| Revenue growth | 12.9% YoY for Q1 FY27 |
|---|---|
| Margins | EBITDA margin improved 250 bps YoY to 26.3%. |
| Demand visibility | Strong recovery in acute; double-digit growth in Mankind and BSV businesses. |
| Management confidence | High, citing disciplined execution and strengthening business fundamentals. |
Growth
Revenue reached INR 4,031 Cr (+12.9% YoY); EBITDA at INR 1,060 Cr (+24.7% YoY) with 26.3% margin.
Outlook
Focused on increasing chronic share (currently 39.6%) and integrating BSV specialty business for long-term sustainable growth.
Risks
Softness in consumer healthcare growth (4% YoY) due to discontinued cash and carry business base effect.
Last quarter's promises, checked
Delivered
- Guided 25-26% EBITDA margin → delivered 26.3% (= BEAT)
- Guided double-digit domestic growth → delivered 12.9% (= BEAT)
- Guided high-teens/20% exports growth → delivered 29% (= BEAT)
Partly delivered
- Guided 39% chronic share → delivered 39.6% (= PARTIAL)
Missed
- Guided double-digit consumer growth → delivered 4% (= MISS)
Investor Presentation filed with NSE, NSE: MANKIND. Summary written with AI assistance from the document.
Mankind Pharma Ltd: key numbers
- Share price
- ₹2,474.90
- Market cap
- ₹1,02,225 Cr
- Revenue (annual)
- ₹14,278 Cr
- Net profit (annual)
- ₹1,913 Cr
- P/E (TTM)
- 50.0×Sector 50.4×
- Promoter holding
- 72.63%-0.03% QoQ
- FII holding
- 9.45%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mankind Pharma Ltd
All →Mankind Pharma Annual General Meeting
Mankind Pharma announced the successful passing of a special resolution to appoint Mr. Anish Vanraj Bafna as a Non-Executive Independent Director. The Postal Ballot concluded with the required majority.
Mankind Pharma Other Announcement
Mankind Pharma has been assigned an ESG rating of 68.21 ('Leader' category) by Niche99 ESG Ratings, based on publicly available data for FY 2025-26.
Mankind Pharma Merger & Restructuring
Mankind Pharma announced that members of its wholly-owned subsidiary, Bharat Serums and Vaccines Limited (BSVL), approved its voluntary liquidation in an EGM.
Mankind Pharma Earnings Call Transcript: Key Takeaways
Mankind Pharma's FY25 ESG report highlights a 73% carbon reduction since FY21 and 63% renewable energy mix. The company is focused on embedding sustainable practices across manufacturing and its value chain.
Mankind Pharma Q1 FY27 Results: Net Profit ₹574.1 Cr, Up 29.1% YoY
Mankind Pharma Ltd reported revenue from operations of ₹4,031 Cr (+12.9% YoY) and net profit of ₹574.1 Cr (+29.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹574.1 Cr · +29.1% YoY
Mankind Pharma Earnings Call: Key Takeaways
Mankind Pharma reported strong Q4 FY26 results with 11.8% revenue growth and 27.1% EBITDA margins, driven by chronic therapy outperformance and steady recovery in acute segments.